Ampio Pharmaceuticals Inc

ASE:AMPE   3:59:53 PM EDT
1.31
-0.05 (-3.68%)
Products, Regulatory

Ampio Provides Update On Osteoarthritis Of The Knee (Oak) Program, Reiterates Compelling Data In Earlier Phase Iii Trials Of Ampion In Severe Oak

Published: 06/17/2021 13:23 GMT
Ampio Pharmaceuticals Inc (AMPE) - Ampio Provides Update on Osteoarthritis of the Knee (oak) Program, Reiterates Compelling Data in Earlier Phase Iii Trials of Ampion in Severe Oak.
Ampio Pharmaceuticals Inc - Pooled Data From Ap-003-c Phase Iii Clinical Trial Show an Even Greater Statistical Significance.
Ampio Pharmaceuticals Inc - FDA Has Provided Written Confirmation That Ap-003-a Study Provides Evidence of Effectiveness of Ampion.